<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about EU</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Wed, 22 May 2013 22:03:06 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=EU" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/pimco-how-to-turn-the-ecb-straggler-into-a-central-bank-pacemaker-cm247869">
      <guid isPermaLink="false">247869</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iVGKZH-PJfY/pimco-how-to-turn-the-ecb-straggler-into-a-central-bank-pacemaker-cm247869</link>
      <category>Investing</category>
      <category>Stocks</category>
      <title>PIMCO: How to Turn the ECB Straggler Into a Central Bank Pacemaker</title>
      <description>Editor's note: This article by Myles Bradshaw originally appeared on  PIMCO  .     The U.S. Federal Reserve (Fed), Bank of Japan (BoJ) and Bank of England (BoE) have all been heavily engaged in&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/iVGKZH-PJfY" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 22 May 2013 18:27:00 Z</pubDate>
      <a10:updated>2013-05-22T16:28:33Z</a10:updated>
      <author>PIMCO</author>
      <nasdaq:tickers>CPI</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>WIT</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/pimco-how-to-turn-the-ecb-straggler-into-a-central-bank-pacemaker-cm247869</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/avoid-these-3-eurozone-etfs-this-summer-etf-news-and-commentary-cm247759">
      <guid isPermaLink="false">247759</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3th5oyXru6I/avoid-these-3-eurozone-etfs-this-summer-etf-news-and-commentary-cm247759</link>
      <category>Investing</category>
      <category>ETFs</category>
      <title>Avoid These 3 Eurozone ETFs This Summer - ETF News And Commentary</title>
      <description>The Euro zone has seen weak GDP growth for yet another quarter, dropping 0.2% in Q1. Though this marks an improvement from the previous quarter's decline of -0.6%, it is yet another major blow&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/3th5oyXru6I" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 22 May 2013 16:25:14 Z</pubDate>
      <a10:updated>2013-05-22T13:33:50Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>EZU</nasdaq:tickers>
      <nasdaq:tickers>FEZ</nasdaq:tickers>
      <nasdaq:tickers>FXE</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/avoid-these-3-eurozone-etfs-this-summer-etf-news-and-commentary-cm247759</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/pm-misses-shipments-currency-blamed-analyst-blog-cm239120">
      <guid isPermaLink="false">239120</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2spfxTh4Oj8/pm-misses-shipments-currency-blamed-analyst-blog-cm239120</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>PM Misses, Shipments &amp; Currency Blamed - Analyst Blog</title>
      <description>Philip Morris International Inc.  (  PM  ) reported adjusted first-quarter 2013 earnings per share of $1.29, missing the Zacks Consensus Estimate by 4.4% but surpassing the comparable&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2spfxTh4Oj8" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 22 Apr 2013 18:17:40 Z</pubDate>
      <a10:updated>2013-04-22T15:19:27Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>FLO</nasdaq:tickers>
      <nasdaq:tickers>GMCR</nasdaq:tickers>
      <nasdaq:tickers>K</nasdaq:tickers>
      <nasdaq:tickers>PM</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/pm-misses-shipments-currency-blamed-analyst-blog-cm239120</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/mastercard-under-scrutiny-in-eu-analyst-blog-cm236081">
      <guid isPermaLink="false">236081</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mDzu7SPnot0/mastercard-under-scrutiny-in-eu-analyst-blog-cm236081</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>MasterCard Under Scrutiny in EU - Analyst Blog</title>
      <description>On Tuesday, the European Union Commission (EUC) disclosed that card giant -  MasterCard Inc.  (  MA  ) is being investigated for charging excess processing or interchange fees to the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/mDzu7SPnot0" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 12 Apr 2013 00:07:26 Z</pubDate>
      <a10:updated>2013-04-11T21:10:29Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>FISV</nasdaq:tickers>
      <nasdaq:tickers>MA</nasdaq:tickers>
      <nasdaq:tickers>TSS</nasdaq:tickers>
      <nasdaq:tickers>V</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/mastercard-under-scrutiny-in-eu-analyst-blog-cm236081</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/ups-challenges-eu-verdict-on-tnt-analyst-blog-cm234811">
      <guid isPermaLink="false">234811</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UvJDwK--g18/ups-challenges-eu-verdict-on-tnt-analyst-blog-cm234811</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>UPS Challenges EU Verdict on TNT - Analyst Blog</title>
      <description>United Parcel Service, Inc.  (  UPS  ) and TNT Express have once hit the headlines for their attempt to win back the lost ground on proposed acquisition plans. Going by market reports, UPS has&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/UvJDwK--g18" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 09 Apr 2013 03:07:16 Z</pubDate>
      <a10:updated>2013-04-09T01:07:39Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ATSG</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>EXPD</nasdaq:tickers>
      <nasdaq:tickers>FDX</nasdaq:tickers>
      <nasdaq:tickers>UPS</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/ups-challenges-eu-verdict-on-tnt-analyst-blog-cm234811</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/biomarin-files-cta-for-bmn190-analyst-blog-cm233234">
      <guid isPermaLink="false">233234</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UuAkWJ_jLwI/biomarin-files-cta-for-bmn190-analyst-blog-cm233234</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>BioMarin Files CTA for BMN-190 - Analyst Blog</title>
      <description>BioMarin Pharmaceutical Inc.  (  BMRN  ) recently submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for BMN-190.&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/UuAkWJ_jLwI" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 03 Apr 2013 18:22:52 Z</pubDate>
      <a10:updated>2013-04-03T15:26:51Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ARRY</nasdaq:tickers>
      <nasdaq:tickers>ATHX</nasdaq:tickers>
      <nasdaq:tickers>BMRN</nasdaq:tickers>
      <nasdaq:tickers>CYTK</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/biomarin-files-cta-for-bmn190-analyst-blog-cm233234</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/bmrn-seeks-us-approval-of-vimizim-analyst-blog-cm232929">
      <guid isPermaLink="false">232929</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nDNd_YUv7Wg/bmrn-seeks-us-approval-of-vimizim-analyst-blog-cm232929</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>BMRN Seeks US Approval of Vimizim - Analyst Blog</title>
      <description>BioMarin Pharmaceutical Inc.  (  BMRN  ) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa). BioMarin&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/nDNd_YUv7Wg" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 03 Apr 2013 00:17:57 Z</pubDate>
      <a10:updated>2013-04-02T21:25:52Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ARRY</nasdaq:tickers>
      <nasdaq:tickers>ATHX</nasdaq:tickers>
      <nasdaq:tickers>BMRN</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>KS</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/bmrn-seeks-us-approval-of-vimizim-analyst-blog-cm232929</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/ups-charged-40m-on-fed-probe-analyst-blog-cm232526">
      <guid isPermaLink="false">232526</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oL03uFg25Yk/ups-charged-40m-on-fed-probe-analyst-blog-cm232526</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>UPS Charged $40M on Fed Probe - Analyst Blog</title>
      <description>The charges against   United Parcel Service, Inc.  (  UPS  ) for doing business with illegal online pharmacies finally reached a conclusion after it settled the case with a non-prosecution&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/oL03uFg25Yk" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 02 Apr 2013 03:10:01 Z</pubDate>
      <a10:updated>2013-04-02T00:11:10Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ATSG</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>EXPD</nasdaq:tickers>
      <nasdaq:tickers>FDX</nasdaq:tickers>
      <nasdaq:tickers>UPS</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/ups-charged-40m-on-fed-probe-analyst-blog-cm232526</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/stock-market-news-for-march-26-2013-market-news-cm230911">
      <guid isPermaLink="false">230911</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dv8xor4aA9o/stock-market-news-for-march-26-2013-market-news-cm230911</link>
      <category>Investing</category>
      <category>US Markets</category>
      <title>Stock Market News for March 26, 2013 - Market News</title>
      <description>Benchmarks ended with losses following concerns over the Cyprus bailout and the Euro Zone crisis.  Discouraging comments from the head of the Euro Zone's finance ministers wiped away&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Dv8xor4aA9o" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 26 Mar 2013 18:30:11 Z</pubDate>
      <a10:updated>2013-03-26T15:32:37Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>APOL</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>GE</nasdaq:tickers>
      <nasdaq:tickers>IMF</nasdaq:tickers>
      <nasdaq:tickers>XLI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/stock-market-news-for-march-26-2013-market-news-cm230911</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/positive-data-on-ucbs-neupro-analyst-blog-cm230662">
      <guid isPermaLink="false">230662</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CIiR-kxNSLA/positive-data-on-ucbs-neupro-analyst-blog-cm230662</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Positive Data on UCB's Neupro - Analyst Blog</title>
      <description>UCB  (  UCBJF  ) recently presented data from a study wherein patients suffering from Parkinson's disease (PD) were transferred from an oral PD medication to Neupro.    The non-interventional,&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/CIiR-kxNSLA" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 26 Mar 2013 02:28:35 Z</pubDate>
      <a10:updated>2013-03-25T23:30:01Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AAN</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>GSK</nasdaq:tickers>
      <nasdaq:tickers>LCI</nasdaq:tickers>
      <nasdaq:tickers>RLS</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/positive-data-on-ucbs-neupro-analyst-blog-cm230662</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/ucb-five-prime-collaborate-analyst-blog-cm229622">
      <guid isPermaLink="false">229622</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TENbI5gxAUM/ucb-five-prime-collaborate-analyst-blog-cm229622</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>UCB, Five Prime Collaborate - Analyst Blog</title>
      <description>UCB  (  UCBJF  ) recently announced a strategic deal with Five Prime Therapeutics, Inc. for the discovery of innovative biologics targets and therapeutics for fibrosis-related inflammatory&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/TENbI5gxAUM" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 22 Mar 2013 02:26:57 Z</pubDate>
      <a10:updated>2013-03-21T23:27:04Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNS</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>LCI</nasdaq:tickers>
      <nasdaq:tickers>QLTI</nasdaq:tickers>
      <nasdaq:tickers>UCBJF</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/ucb-five-prime-collaborate-analyst-blog-cm229622</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/philip-morris-beats-gives-view-analyst-blog-cm215642">
      <guid isPermaLink="false">215642</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E6y1dxVyGFI/philip-morris-beats-gives-view-analyst-blog-cm215642</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Philip Morris Beats, Gives View - Analyst Blog</title>
      <description>Philip Morris International Inc.  (  PM  ) reported adjusted third quarter 2012 earnings per share of $1.24, surpassing the comparable prior-year quarter earnings by 12.7%. Excluding currency&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/E6y1dxVyGFI" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 08 Feb 2013 23:09:01 Z</pubDate>
      <a10:updated>2013-02-08T19:52:52Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>FLO</nasdaq:tickers>
      <nasdaq:tickers>K</nasdaq:tickers>
      <nasdaq:tickers>PG</nasdaq:tickers>
      <nasdaq:tickers>PM</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/philip-morris-beats-gives-view-analyst-blog-cm215642</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/good-news-for-ucb-analyst-blog-cm214780">
      <guid isPermaLink="false">214780</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZA0pxZPtqjs/good-news-for-ucb-analyst-blog-cm214780</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Good News for UCB - Analyst Blog</title>
      <description>Good news flowed in at  UCB  (  UCBJF  ) from Europe when the European Union (EU) approved Vimpat (lacosamide) as a single loading dose option for treating patients suffering from partial onset&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ZA0pxZPtqjs" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 07 Feb 2013 02:15:01 Z</pubDate>
      <a10:updated>2013-02-06T22:50:44Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AED</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>SLXP</nasdaq:tickers>
      <nasdaq:tickers>TRGT</nasdaq:tickers>
      <nasdaq:tickers>UCBJF</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/good-news-for-ucb-analyst-blog-cm214780</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/us-steel-earnings-could-be-weak-but-outlook-is-improving-cm211410">
      <guid isPermaLink="false">211410</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eUaqXTBmkng/us-steel-earnings-could-be-weak-but-outlook-is-improving-cm211410</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <category>US Markets</category>
      <title>U.S. Steel Earnings Could Be Weak But Outlook Is Improving</title>
      <description>U.S. Steel (  X  )  will announce its fourth quarter earnings on Tuesday, January  29. We expect weaker revenues and profits compared to Q3 2012.  The economic environment in Europe remains&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/eUaqXTBmkng" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 28 Jan 2013 21:49:01 Z</pubDate>
      <a10:updated>2013-01-28T16:50:13Z</a10:updated>
      <author>Trefis Team</author>
      <nasdaq:tickers>AA</nasdaq:tickers>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>KMP</nasdaq:tickers>
      <nasdaq:tickers>MT</nasdaq:tickers>
      <nasdaq:tickers>X</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/us-steel-earnings-could-be-weak-but-outlook-is-improving-cm211410</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/here-comes-the-trading-tax-real-time-insight-cm210283">
      <guid isPermaLink="false">210283</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KU2VGDolM6M/here-comes-the-trading-tax-real-time-insight-cm210283</link>
      <category>Investing</category>
      <category>Stocks</category>
      <title>Here Comes The Trading Tax! - Real Time Insight</title>
      <description>Big news! -- Passage of the "Tobin Tax" by the European Union (EU).     EU finance ministers cleared the way for 11 members to introduce a trading tax.  This tax can raise&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/KU2VGDolM6M" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 24 Jan 2013 18:02:01 Z</pubDate>
      <a10:updated>2013-01-24T14:22:15Z</a10:updated>
      <author>John Blank</author>
      <nasdaq:tickers>EU</nasdaq:tickers>
      <nasdaq:tickers>EUFN</nasdaq:tickers>
      <nasdaq:tickers>EWU</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/here-comes-the-trading-tax-real-time-insight-cm210283</feedburner:origLink></item>
  </channel>
</rss>
